Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMaxCyte Share News (MXCT)

Share Price Information for MaxCyte (MXCT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 360.00
Bid: 350.00
Ask: 370.00
Change: -10.00 (-2.70%)
Spread: 20.00 (5.714%)
Open: 365.00
High: 365.00
Low: 360.00
Prev. Close: 370.00
MXCT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK TRADING UPDATE SUMMARY: Science Group To Beat Forecasts For 2020

Mon, 11th Jan 2021 14:51

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:

----------

Science Group PLC - Cambridge-based scientific consultancy services firm - Says it expects revenue for 2020 to soar 28% to GBP73 million from GBP57.2 million and for operating profit to beat its previously upgraded forecast of GBP10 million, up from GBP6.7 million in 2019. Says Finance Director Rebecca Archer will step down to take up a new role after completion of the 2020 results audit. Adds it has hired former Ted Baker interim finance director Sameet Vohra as chief financial officer designate.

----------

Rotala PLC - West Midlands-based bus operator - For financial 2020 ended November 30, expects to swing to pretax loss of GBP1.0 million from profit of GBP3.6 million the year before despite an increase in turnover to GBP76.0 million from GBP67.5 million. Blames the performance on Covid-19 lockdowns but notes the UK government grant package, the CBSSG Restart, helped its performance. However, it says the provisions of CBSSG Restart and the associated UK Government measures were designed to ensure it makes neither a profit nor a loss until the measures are terminated. As such, it expects to make neither a profit nor loss for financial 2021.

----------

InnovaDerma PLC - London-based beauty, personal care and life science products firm - Expects revenue for the six months ended December 31 to be around GBP4.1 million, down from GBP5.1 million the year prior, with UK sales declining due to a reduction in beauty category consumption amid the Covid-19 pandemic. Adds it has dismissed Joe Bayer from the role of chair effective immediately with existing Non-Executive Director Ross Andrews to replace him.

----------

W Resources PLC - London-based tungsten, tin and gold mining company with assets in Spain and Portugal - Draws down further GBP500,000 from its GBP4.0 million Atlas Capital Markets convertible bond facility, the second drawdown since the facility was secured in March 2020. This convertible bond tranche has a 5% coupon and 3-year term. The company will use the cash to advance the Regua mine development and provide additional working capital.

----------

AssetCo PLC - Middle East-focused provider of management and resources to the fire and emergency services - Says Aberdeen Asset Management Founder Martin Gilbert, Aberdeen's former global head of private markets Peter McKellar, various associates and funds managed by Toscafund Asset Management acquire a 29.8% stake at 475 pence per share. Following the receipt of regulatory approvals, Martin Gilbert and Peter McKellar will join the board as non-executive directors.

----------

MaxCyte Inc - Maryland-based cell and gene therapies firm - Inks a clinical and commercial licensing agreement with Myeloid Therapeutics to advance Myeloid's cell therapy programmes. Under the deal, Myeloid Therapeutics will obtain non-exclusive clinical and commercial rights to use MaxCyte's Flow Electroporation technology and ExPERT platform. In return, MaxCyte will receive development and approval milestones and sales-based payments, along with other licensing fees. No financial details were disclosed.

----------

Hutchison China Meditech Ltd - China-based biopharmaceutical company - Enters strategic partnership with Inmagene Biopharmaceuticals to further develop four novel preclinical drug candidatesfor the potential treatment of multiple immunological diseases. The companies will work together to move the drug candidates towards investigational new drug submission. If successful, Inmagene will then move the drug candidates through global clinical development. For each of the drug candidates, Chi-Med will be entitled to development milestones of up to USD95 million and up to USD135 million in commercial milestones as well as up to double-digit royalties upon commercialization.

----------

By Ife Taiwo; ifetaiwo@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News
8 May 2019 15:58

MaxCyte begins dosing second cohort in MCY-M11 clinical trial

(Sharecast News) - Clinical-stage, cell-based therapies and life sciences company MaxCyte has initiated dosing for the second cohort of patients in its US phase 1 clinical trial with MCY-M11 - the lead, wholly-owned, non-viral mRNA-based cell therapy candidate from its CARMA platform - it announced on Wednesday.

Read more
8 May 2019 12:11

MaxCyte Dosing Second Patients Group In Phase One Cancer Drug Trial

LONDON (Alliance News) - MaxCyte Inc on Wednesday said it has begun dosing for the second cohort of patients in its phase one trial of cancer drug MCY-M11.Shares in MaxCyte were down 5.7% a

Read more
24 Apr 2019 11:37

MaxCyte Outlook Confident As Loss Narrows In 2018 On Higher Revenue

LONDON (Alliance News) - MaxCyte Inc on Wednesday said its loss narrowed in 2018 on higher annual fees from its partners as it progresses on MCY-M11 therapeutic candidate development.The a

Read more
17 Apr 2019 16:06

UK Earnings, Trading Statements Calendar - Next 7 Days

Thursday 18 April UnileverQ1 ResultsPZ CussonsTrading SolutionsTrading 19 events

Read more
8 Apr 2019 13:58

MaxCyte Launches ExPERT Cellular Engineering Technology Platform

LONDON (Alliance News) - MaxCyte Inc on Monday announced the launch of its new ExPERT technology platform for use in cellular engineering.MaxCyte also noted that its business had produced

Read more
8 Apr 2019 08:34

MaxCyte launches new generation of cellular engineering instruments

(Sharecast News) - MaxCyte on Monday launched its ExPERT technology platform, a family of instruments that are the next generation of its complex cellular engineering technology.

Read more
1 Mar 2019 10:05

MaxCyte Inks Multi-Drug Clinical And Commercial Agreement With Kite

LONDON (Alliance News) - Biotechnology company MaxCyte Inc on Friday said it has expanded its business relationship with Kite by signing a multi-drug clinical and commercial agreement.Under

Read more
5 Feb 2019 17:45

UPDATE: MaxCyte Placing Fully Subscribed; Raises Over GBP10.0 Million (ALLISS)

LONDON (Alliance News) - MaxCyte Inc on Tuesday said it has raised GBP10.0 million from a placing of 5.9 million shares at 170 pence each.The life sciences company placed 5.9 million just

Read more
5 Feb 2019 10:22

MaxCyte To Raise At Least GBP10 Million For Future Growth Plans (ALLISS)

LONDON (Alliance News) - MaxCyte Inc on Tuesday said it plans to raise at least GBP10 million via a placing of shares in order to accelerate its growth strategy.The life sciences company no

Read more
15 Jan 2019 11:18

MaxCyte Guides For Revenue Growth And Earnings Above Expectations

LONDON (Alliance News) - MaxCyte Inc on Tuesday guided for a 19% increase in its 2018 revenue with the firm expecting its annual earnings to exceed market views.The life science company in

Read more
24 Oct 2018 16:07

UK Shareholder Meetings Calendar - Next 7 Days

Thursday 25 OctoberGreen & Smart WoodsAlumasc GroupFriday 26 OctoberArgos Capital

Read more
10 Oct 2018 11:47

MaxCyte Begins Patient Trial Of Proposed Cancer Treatment MCY-M11

LONDON (Alliance News) - Life sciences and medicines company MaxCyte Inc on Wednesday said it has dosed the first patient in its phase I trial for MCY-M11.MCY-M11 is a mesothelin targeting

Read more
24 Sep 2018 10:18

MaxCyte Interim Revenue Rises But Loss Widens On CARMA Development

LONDON (Alliance News) - MaxCyte Inc on Monday said its loss widened in the first half of 2018 as it continued to invest in the development of its CARMA drug platform.The life sciences said

Read more
17 Sep 2018 16:09

UK Earnings, Trading Statements Calendar - Next 7 Days

Tuesday 18 September Ocado GroupTrading Statement DP PolandHalf Year Year Year Year

Read more
26 Jul 2018 17:50

DIRECTOR DEALINGS: Wife Of MaxCyte Non-Executive Director Buys Shares

LONDON (Alliance News) - Medical & technology company MaxCyte Inc said that Karin Johnston, wife of Non-Executive Director John Johnston, purchased 11,500 shares at a price of 240 pence per on

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.